Auris Medical Stock Price, News & Analysis (NASDAQ:EARS)

$0.44 0.00 (0.00 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$0.44
Today's Range$0.44 - $0.46
52-Week Range$0.38 - $1.39
Volume668,277 shs
Average Volume489,844 shs
Market Capitalization$21.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.59

About Auris Medical (NASDAQ:EARS)

Auris Medical logoAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EARS
CUSIPN/A
Phone41-41-729-7194

Debt

Debt-to-Equity Ratio-14.04%
Current Ratio1.86%
Quick Ratio1.86%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.42 per share
Price / Book1.05

Profitability

Trailing EPS($0.65)
Net Income$-31,130,000.00
Net MarginsN/A
Return on Equity-343.01%
Return on Assets-80.81%

Miscellaneous

Employees24
Outstanding Shares46,070,000

Auris Medical (NASDAQ:EARS) Frequently Asked Questions

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

How were Auris Medical's earnings last quarter?

Auris Medical Holding AG (NASDAQ:EARS) announced its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.08. View Auris Medical's Earnings History.

When will Auris Medical make its next earnings announcement?

Auris Medical is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Auris Medical.

Where is Auris Medical's stock going? Where will Auris Medical's stock price be in 2017?

2 brokers have issued 1-year price targets for Auris Medical's shares. Their forecasts range from $4.00 to $5.00. On average, they expect Auris Medical's share price to reach $4.50 in the next twelve months. View Analyst Ratings for Auris Medical.

What are Wall Street analysts saying about Auris Medical stock?

Here are some recent quotes from research analysts about Auris Medical stock:

  • 1. According to Zacks Investment Research, "Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. " (10/11/2017)
  • 2. Needham & Company LLC analysts commented, "EARS reported 4Q16 financials and update its three ongoing development programs. The next key data catalyst for EARS will be ph 3 HEALOS results for AM-111 (hearing loss) in 3Q17. The study, which should complete enrollment in 2Q17, is the first of two AM-111 pivotal studies in hearing loss. The Keyzilen program will first report results from the open-label studies (AMPACT-1 and 2) in 2Q17 while the recently modified TACCT3 study is on track to have top-line results in 1Q18. EARS plans to evaluate AM-125 (Meniere's disease/vertigo) in an additional ph 1 trial (initiating in 2H17) prior to discussing a regulatory pathway with regulatory authorities. The current EARS market valuation appears to place minimal to no value on any of the ongoing clinical programs.We maintain our Buy rating and adjust our $PT to $4 (from $5)." (3/14/2017)

Are investors shorting Auris Medical?

Auris Medical saw a drop in short interest in November. As of November 30th, there was short interest totalling 648,081 shares, a drop of 31.3% from the November 15th total of 943,665 shares. Based on an average daily volume of 2,302,699 shares, the days-to-cover ratio is presently 0.3 days. Currently, 2.7% of the company's shares are short sold.

Who are some of Auris Medical's key competitors?

Who are Auris Medical's key executives?

Auris Medical's management team includes the folowing people:

  • Thomas Meyer, Chairman of the Board, Chief Executive Officer (Age 48)
  • Hernan Levett, Chief Financial Officer
  • Anne Sabine Zoller, General Counsel (Age 36)
  • Cindy McGee, Head of Investor Relations and Corporate Communications
  • Andrea Braun, Head of Regulatory and Quality Affairs
  • Thomas Jung M.D., Ph.D., Chief Development Officer
  • Bettina Mirella Stubinski, Chief Medical Officer (Age 49)
  • James I. Healy M.D. Ph.D., Non-Executive Independent Vice Chairman of the Board (Age 52)
  • Wolfgang Arnold, Non-Executive Independent Director (Age 74)
  • Oliver Kubli, Non-Executive Independent Director (Age 43)

How do I buy Auris Medical stock?

Shares of Auris Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auris Medical's stock price today?

One share of Auris Medical stock can currently be purchased for approximately $0.44.

How big of a company is Auris Medical?

Auris Medical has a market capitalization of $21.19 million. The biotechnology company earns $-31,130,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Auris Medical employs 24 workers across the globe.

How can I contact Auris Medical?

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]


MarketBeat Community Rating for Auris Medical (EARS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Auris Medical (NASDAQ:EARS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.802.802.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$7.00$7.00$7.13
Price Target Upside: 529.37% upside879.02% upside879.02% upside886.16% upside

Auris Medical (NASDAQ:EARS) Consensus Price Target History

Price Target History for Auris Medical (NASDAQ:EARS)

Auris Medical (NASDAQ:EARS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/1/2017Roth CapitalReiterated RatingBuy$5.00LowView Rating Details
3/14/2017Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00HighView Rating Details
11/11/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
6/15/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
6/10/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Auris Medical (NASDAQ:EARS) Earnings History and Estimates Chart

Earnings by Quarter for Auris Medical (NASDAQ:EARS)

Auris Medical (NASDAQ EARS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018        
8/10/20176/30/2017($0.21)($0.12)ViewN/AView Earnings Details
5/11/20173/31/2017($0.14)($0.22)ViewN/AView Earnings Details
3/14/201712/31/2016($0.29)($0.16)ViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)ViewListenView Earnings Details
5/11/2016Q116($0.23)($0.26)ViewListenView Earnings Details
3/14/2016Q415($0.29)($0.16)ViewListenView Earnings Details
11/12/2015Q315($0.28)($0.16)ViewListenView Earnings Details
8/19/2015Q215($0.23)($0.36)ViewListenView Earnings Details
5/28/2015Q115($0.22)($0.29)ViewListenView Earnings Details
3/19/2015Q4($0.23)($0.17)ViewListenView Earnings Details
12/3/2014Q3($0.24)($0.14)ViewN/AView Earnings Details
9/15/2014Q2 2014($0.34)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Auris Medical (NASDAQ:EARS) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Auris Medical (NASDAQ:EARS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Auris Medical (NASDAQ EARS)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Auris Medical (NASDAQ EARS) News Headlines

Source:
DateHeadline
Contrasting Auris Medical (EARS) & The CompetitionContrasting Auris Medical (EARS) & The Competition
www.americanbankingnews.com - December 14 at 5:40 PM
Who Really Owns Auris Medical Holding AG (EARS)?Who Really Owns Auris Medical Holding AG (EARS)?
finance.yahoo.com - December 8 at 5:00 PM
Pre-market Technical Scan on Biotech Equities -- Viking Therapeutics, RXi Pharma, Kitov Pharma, and Auris Medical - PR Newswire (press release)Pre-market Technical Scan on Biotech Equities -- Viking Therapeutics, RXi Pharma, Kitov Pharma, and Auris Medical - PR Newswire (press release)
www.prnewswire.com - December 4 at 5:05 PM
Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - BenzingaMid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - Benzinga
www.benzinga.com - November 29 at 5:25 PM
Auris Medical Holding (EARS) Announces Top-Line Results from ... - StreetInsider.comAuris Medical Holding (EARS) Announces Top-Line Results from ... - StreetInsider.com
www.streetinsider.com - November 29 at 5:25 PM
Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - NasdaqMid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - Nasdaq
www.nasdaq.com - November 29 at 9:54 AM
EARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark - NasdaqEARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark - Nasdaq
www.nasdaq.com - November 29 at 9:54 AM
Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - November 29 at 9:54 AM
[$$] Decibel Therapeutics, Regeneron Strike Deal for Hearing Treatments[$$] Decibel Therapeutics, Regeneron Strike Deal for Hearing Treatments
finance.yahoo.com - November 29 at 9:54 AM
Edited Transcript of EARS earnings conference call or presentation 28-Nov-17 1:00pm GMTEdited Transcript of EARS earnings conference call or presentation 28-Nov-17 1:00pm GMT
finance.yahoo.com - November 29 at 9:54 AM
Auris Medical (EARS) Announces Quarterly  Earnings Results, Beats Expectations By $0.06 EPSAuris Medical (EARS) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - November 28 at 9:48 PM
Auris Medical Holding (EARS) Tops Q3 EPS by 3cAuris Medical Holding (EARS) Tops Q3 EPS by 3c
www.streetinsider.com - November 28 at 5:02 PM
UPDATE 2-Auris Medical shares plunge as deafness drug trial scrappedUPDATE 2-Auris Medical shares plunge as deafness drug trial scrapped
www.reuters.com - November 28 at 5:02 PM
Here’s What Triggered Auris Medical Holding AG (EARS) SelloffHere’s What Triggered Auris Medical Holding AG (EARS) Selloff
finance.yahoo.com - November 28 at 5:02 PM
Auris Medical Holding AG (EARS) Expected to Post Earnings of -$0.20 Per ShareAuris Medical Holding AG (EARS) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - November 28 at 11:14 AM
1-Auris shares tank as it plans to end key trial for deafness drug1-Auris' shares tank as it plans to end key trial for deafness drug
finance.yahoo.com - November 28 at 8:48 AM
Auris Medical Holding AG to Host Earnings CallAuris Medical Holding AG to Host Earnings Call
finance.yahoo.com - November 28 at 8:48 AM
Auris reports 3Q lossAuris reports 3Q loss
finance.yahoo.com - November 28 at 8:48 AM
Auris Medical to abandon hearing-loss drug trialAuris Medical to abandon hearing-loss drug trial
finance.yahoo.com - November 28 at 8:48 AM
Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business UpdateAuris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update
feeds.benzinga.com - November 28 at 7:11 AM
Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden DeafnessAuris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
feeds.benzinga.com - November 28 at 7:11 AM
Auris Medical News Release - GlobeNewswire (press release)Auris Medical News Release - GlobeNewswire (press release)
globenewswire.com - November 22 at 11:54 PM
Auris Medical News ReleaseAuris Medical News Release
finance.yahoo.com - November 21 at 6:20 PM
Auris Medical Holding AG (EARS) Set to Announce Quarterly Earnings on TuesdayAuris Medical Holding AG (EARS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 21 at 1:54 AM
Are You Keeping An Eye On EARS And 6 Other Pharma Stocks?Are You Keeping An Eye On EARS And 6 Other Pharma Stocks?
www.rttnews.com - November 17 at 12:45 PM
Auris Medical: Clinical Updates and Potential CatalystsAuris Medical: Clinical Updates and Potential Catalysts
finance.yahoo.com - November 10 at 11:44 AM
-$0.20 EPS Expected for Auris Medical Holding AG (EARS) This Quarter-$0.20 EPS Expected for Auris Medical Holding AG (EARS) This Quarter
www.americanbankingnews.com - November 9 at 9:22 PM
What You Must Know About Auris Medical Holding AG’s (EARS) Financial StrengthWhat You Must Know About Auris Medical Holding AG’s (EARS) Financial Strength
finance.yahoo.com - November 9 at 1:20 AM
Auris Medical Holding AG (EARS) Scheduled to Post Quarterly Earnings on WednesdayAuris Medical Holding AG (EARS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:06 AM
Short Interest in Auris Medical Holding AG (EARS) Grows By 29.7%Short Interest in Auris Medical Holding AG (EARS) Grows By 29.7%
www.americanbankingnews.com - October 28 at 1:26 AM
Auris Medical Holding AG (EARS) Expected to Announce Earnings of -$0.20 Per ShareAuris Medical Holding AG (EARS) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - October 21 at 2:20 AM
Edited Transcript of EARS earnings conference call or presentation 14-Mar-16 12:00pm GMTEdited Transcript of EARS earnings conference call or presentation 14-Mar-16 12:00pm GMT
finance.yahoo.com - October 16 at 3:25 AM
Corporate News Blog - Auris Medical Executes Two Share Purchase Agreements with Lincoln Park Capital FundCorporate News Blog - Auris Medical Executes Two Share Purchase Agreements with Lincoln Park Capital Fund
finance.yahoo.com - October 13 at 6:38 PM
BRIEF-Auris Medical Holding AG files for resale of up to 7.2 mln common sharesBRIEF-Auris Medical Holding AG files for resale of up to 7.2 mln common shares
www.reuters.com - October 12 at 6:54 PM
Auris Medical Holding (EARS) Reports Two Share Purchase Agreements for up to $15M with Lincoln Park Capital Fund - StreetInsider.comAuris Medical Holding (EARS) Reports Two Share Purchase Agreements for up to $15M with Lincoln Park Capital Fund - StreetInsider.com
www.streetinsider.com - October 12 at 5:42 AM
Zacks Investment Research Downgrades Auris Medical Holding AG (EARS) to HoldZacks Investment Research Downgrades Auris Medical Holding AG (EARS) to Hold
www.americanbankingnews.com - October 11 at 11:02 PM
BRIEF-Auris Medical announces share purchase agreements with Lincoln Park Capital FundBRIEF-Auris Medical announces share purchase agreements with Lincoln Park Capital Fund
www.reuters.com - October 11 at 7:38 PM
Auris Medical Holding (EARS) Reports Two Share Purchase Agreements for up to $15M with Lincoln Park Capital FundAuris Medical Holding (EARS) Reports Two Share Purchase Agreements for up to $15M with Lincoln Park Capital Fund
www.streetinsider.com - October 11 at 7:38 PM
Auris Medical Announces Transfer to Nasdaq Capital MarketAuris Medical Announces Transfer to Nasdaq Capital Market
www.nasdaq.com - September 28 at 9:05 AM
BRIEF-Auris Medical provides board of directors updateBRIEF-Auris Medical provides board of directors update
www.reuters.com - September 28 at 12:08 AM
Auris Medical Provides Board of Directors Update - GlobeNewswire (press release)Auris Medical Provides Board of Directors Update - GlobeNewswire (press release)
globenewswire.com - September 27 at 7:07 PM
Auris Medical Provides Board of Directors UpdateAuris Medical Provides Board of Directors Update
feeds.benzinga.com - September 26 at 9:34 AM
Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches EyesOpdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes
www.rttnews.com - September 25 at 11:37 AM
Auris Medical Holding AG (EARS) versus Catalyst Pharmaceuticals (CPRX) Financial ContrastAuris Medical Holding AG (EARS) versus Catalyst Pharmaceuticals (CPRX) Financial Contrast
www.americanbankingnews.com - September 24 at 6:20 PM
BRIEF-Auris Medical completes patient recruitment for phase 3 trial of Keyzilen in acute and post-acute tinnitusBRIEF-Auris Medical completes patient recruitment for phase 3 trial of Keyzilen in acute and post-acute tinnitus
www.reuters.com - September 22 at 5:10 PM
Auris Medical Holding (EARS) Reports Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen - StreetInsider.comAuris Medical Holding (EARS) Reports Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen - StreetInsider.com
www.streetinsider.com - September 22 at 8:46 AM
Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute TinnitusAuris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus
finance.yahoo.com - September 22 at 8:46 AM
Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27
finance.yahoo.com - September 20 at 7:00 PM
Why Auris Medical Holding AG (EARS) Could Be A BuyWhy Auris Medical Holding AG (EARS) Could Be A Buy
finance.yahoo.com - September 15 at 11:43 PM
Auris Medical to Host Scientific Symposium at the AAO-HNSF ... - GlobeNewswire (press release)Auris Medical to Host Scientific Symposium at the AAO-HNSF ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 5:51 AM

SEC Filings

Auris Medical (NASDAQ:EARS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Auris Medical (NASDAQ:EARS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Auris Medical (NASDAQ EARS) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.